NervGen Pharma (NASDAQ:NGEN) Upgraded by Wall Street Zen to Hold Rating

NervGen Pharma (NASDAQ:NGEN) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Several other research analysts have also issued reports on the stock. Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a research report on Thursday, April 23rd. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. TD Cowen initiated coverage on NervGen Pharma in a research note on Thursday, June 11th. They set a “buy” rating for the company. Leerink Partners assumed coverage on NervGen Pharma in a report on Monday, July 13th. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Weiss Ratings began coverage on NervGen Pharma in a research report on Friday, April 24th. They set a “sell (d-)” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NervGen Pharma Price Performance

Shares of NGEN opened at $1.67 on Monday. The stock has a 50 day simple moving average of $2.27. The firm has a market cap of $134.65 million and a PE ratio of -18.56. NervGen Pharma has a 12-month low of $1.59 and a 12-month high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last released its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.